Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics

Arcus Biosciences, Inc. (RCUS): $16.53

0.72 (+4.55%)

POWR Rating

Component Grades








Add RCUS to Watchlist
Sign Up

Industry: Biotech




#95 of 356

in industry

RCUS Price/Volume Stats

Current price $16.53 52-week high $25.47
Prev. close $15.81 52-week low $12.95
Day low $15.65 Volume 446,314
Day high $16.55 Avg. volume 748,383
50-day MA $16.05 Dividend yield N/A
200-day MA $16.92 Market Cap 1.50B

RCUS Stock Price Chart Interactive Chart >

Arcus Biosciences, Inc. (RCUS) Company Bio

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.

RCUS Latest News Stream

Event/Time News Detail
Loading, please wait...

RCUS Latest Social Stream

Loading social stream, please wait...

View Full RCUS Social Stream

Latest RCUS News From Around the Web

Below are the latest news stories about ARCUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RCUS as an investment opportunity.

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., December 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and

Yahoo | December 11, 2023

We Think Arcus Biosciences (NYSE:RCUS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 9, 2023

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Yahoo | December 7, 2023

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

Yahoo | December 5, 2023

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

ALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis

Yahoo | December 4, 2023

Read More 'RCUS' Stories Here

RCUS Price Returns

1-mo -3.39%
3-mo -12.91%
6-mo -8.77%
1-year -15.66%
3-year -32.67%
5-year 99.64%
YTD -13.46%
2023 -7.64%
2022 -48.90%
2021 55.89%
2020 157.03%
2019 -6.22%

Continue Researching RCUS

Want to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:

Arcus Biosciences Inc (RCUS) Stock Price | Nasdaq
Arcus Biosciences Inc (RCUS) Stock Quote, History and News - Yahoo Finance
Arcus Biosciences Inc (RCUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!